Abstract
The Icatibant Outcome Survey (IOS; NCT01034969) monitors icatibant safety and effectiveness in a real-world setting. While icatibant is licensed in numerous countries for hereditary angioedema (HAE) attacks in adults with C1-INH deficiency, we report IOS data for off-label use in angioedema due to acquired C1-INH deficiency. This condition shares a mechanism and clinical profile with HAE, but is less prevalent.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
